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Abstract
For decades, newborn screening was the only public health program in the US focused on 
reducing morbidity, mortality and disability in people affected by genetic conditions. The 
landscape has changed, however, as evidence-based recommendations are now available for 
several other genomic applications that can save lives now in the US. Many more such 
applications are expected to emerge in the next decade. An action plan, based on evidence, 
provides the impetus for a new paradigm for public health practice in genomics across the lifespan 
using established multilevel processes as a guide. These include policy interventions, education, 
clinical interventions, and surveillance. Applying what we know today in hereditary breast/ovarian 
cancer, Lynch syndrome and familial hypercholesterolemia has the potential to affect thousands of 
people in the US population every year. Enhanced partnerships between genetic and nongenetic 
providers of clinical medicine and public health are needed to overcome the challenges for 
implementing genomic medicine applications both now and in the future.
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Background
Advances in genomics and related fields created expectations for a flood of new health-
related applications, such as tests and interventions that could reduce the burden of common 
complex diseases in populations. However, while there are an increasing number of genomic 
applications that are progressing from bench to bedside (a total of 419 were identified from 
horizon scanning on May 1, 2012), few have actually been widely adopted in clinical 
practice, mainly because of the insufficient evidence base to support their use [1].
While most emerging genomic applications will be implemented in a clinical health care 
setting, there remains a crucial role for state-based public health programs. Newborn 
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screening (NBS), the first widely administered state-based public health program in the US 
aimed at reducing morbidity and mortality in people with certain genetic conditions through 
early diagnosis, began in 1963 as a means to find infants with phenylketonuria and has 
grown to become an integral component of public health practice [2]. At present, the 
Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children 
recommends 31 core conditions for NBS, many of which are single gene disorders [3]. NBS 
can identify about 12,500 infants every year who are in need of timely intervention to 
improve health outcomes [4]. A strong rationale for public health intervention exists because 
many infants with these conditions would not otherwise be diagnosed by the clinical health 
care system alone in time for early and effective interventions to prevent mortality, 
morbidity and disability. While considered a traditional component of public health, NBS 
continues to adapt and improve and may benefit from next-generation sequencing or whole-
genome sequencing in the near future.
We have now reached a point in the development of genomics such that new public health 
programs are needed for active interventions beyond NBS. These include an increasing 
number of conditions that are currently poorly ascertained by health care and for which 
evidence-based recommendations for improving health are already available.
To consider the readiness of genomic applications for practice, a useful framework for 
public health has been proposed by Khoury et al. [5]. The framework considers, in the 
context of intended use, a genomic application’s analytic validity, clinical validity, clinical 
utility, balance of benefits and harms, and the existence of an evidencebased 
recommendation. The tiers of the classification system are characterized as follows:
Tier 1 applications have demonstrated analytic validity, clinical validity, clinical utility, and 
there are evidenced-based guidelines encouraging their use.
Tier 2 applications have demonstrated analytic and clinical validity, hold promise for 
demonstrating clinical utility (e.g. when benefits in terms of patient outcomes are highly 
plausible, and well-designed trials with appropriately selected endpoints are known to be 
planned or in progress), but no evidence-based guidelines recommending clinical use. Such 
applications may provide information for informed decision-making.
Tier 3 applications have not yet demonstrated adequate analytic validity, clinical validity or 
clinical utility, or have demonstrated evidence of harms. The use of such applications should 
be discouraged in practice, but may be considered for use in research in some instances.
In this commentary, we focus entirely on tier 1 applications. In table 1 below and in the 
Appendix, we list details on 3 such genomic applications. Several categories of information 
are compiled for each, including: public health burden and context, the existence of an 
evidence-based recommendation, intended use; status of current practice, potential impact, 
and evidence of cost effectiveness. The CDC Office of Public Health Genomics website 
(http://www.cdc.gov/genomics/) maintains an updated list of tier 1–3 genomic applications 
(http://www.cdc.gov/genomics/gtesting/tier.htm).
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Tier 1 Genomic Applications: Opportunities and Challenges for Public 
Health Interventions to Save Lives
In 2005, the US Preventive Services Task Force (USPSTF) recommended offering genetic 
counseling for the use of BRCA1/2 testing in women with a strong family history of breast 
and/or ovarian cancer [6]. Two other genomic applications have since met the tier 1 criteria 
through evidence review and recommendations by independent, evidence-based panels. In 
2008, the UK’s National Institute for Health and Clinical Excellence recommended cascade 
screening in relatives of patients with familial hypercholesterolemia (FH) to prevent cardio - 
vascular morbidity and mortality among affected relatives [7]. In 2009, the US-based 
Evaluation of Genomic Applications in Practice and Prevention Working Group 
recommended genetic testing for Lynch syndrome (LS) among all newly diagnosed 
colorectal cancer (CRC) cases to reduce morbidity and mortality in relatives through testing 
and surveillance as appropriate [8]. These 3 recommendations concern autosomal dominant 
disorders with health implications throughout life and use family health history information 
to identify those at risk in order to cascade from an affected person to the rest of the family. 
Also, one common feature among all 3 is that the health care system alone has not optimally 
identified people with these diseases to benefit their relatives (see below and table 1). A 
notable difference among the 3 is ascertainment in that implementation of the USPSTF 
BRCA recommendation begins with unaffected women in the general population, whereas 
the others begin with people affected by the disease of interest. Public health action, based 
on these evidence-based recommendations to leverage family history and/or cascade 
screening with policy changes, provides the immediate potential to reach thousands of 
people in the US each year. Two of these applications, BRCA1/2 and LS, are now part of the 
Healthy People 2020 objectives from the US Department of Health and Human Services [9].
The theoretical reach for public health genomic interventions beyond NBS must be 
considered in the light of many challenges and limitations, however. Implementation will be 
complex in the US because it must occur within a health care system that, unlike many 
European countries and Canada, is not interconnected or centrally coordinated, and in which 
exists widely varying coverage depending on individual insurance plans and resources. This 
is a challenge not only because there is a wide disparity in health care coverage for non-NBS 
tier 1 applications, but also because cascade screening, which can be helpful if not critical 
for all 3 diseases, must identify and provide interventions to relatives who are likely not in 
the same payer network and whose health records are not linked. Also, there are privacy 
concerns when cascade screening is used to contact the relatives of a patient who has already 
been diagnosed or is known to have a specific genetic condition. Unlike the case with NBS, 
there are no universal screening programs in the US to identify people recommended for 
these applications; nor at present can the case be made for population screening of these 
applications in the US in the absence of pilot or demonstration programs to show scalability 
and effectiveness in the real world [10]. Further, many who should have the test may not 
have the resources to pay for either the genetic testing or the follow-up treatments or 
screenings which might be indicated. Unlike NBS, there are no mandated statewide public 
health systems in place to implement and measure non-NBS test use or to follow up on the 
results. Finally, fundamental resistance to system change can only be overcome with 
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effective communication of the rewards for taking action, especially to budget and policy 
decision makers.
While these challenges are considerable, there are some impactful tier 1 opportunities that 
can be taken advantage of now for a relatively low amount of public health investment to 
promote and monitor ascertainment for tier 1 genomic applications by health care. 
Regardless, it is clear that successful ascertainment for tier 1 genomic applications beyond 
NBS in the US will require nontraditional partnerships between state public health 
departments and numerous health care payers and providers. A brief review of the 3 
example conditions and the respective potential population impact of public health 
implementation strategies that complement clinical care are shown in table 1 and in the 
Appendix.
What Can Public Health Do Now? – Multilevel Interventions
To tackle these substantial challenges, it is useful to consider multilevel public health 
approaches, using the core public health functions of assessment, policy development and 
assurance [5, 11]. Dr. Thomas Frieden, the current director of the CDC, has proposed a 
health impact pyramid to assess the potential impact of different types of interventions [12]. 
This was recently discussed in the context of human genomic applications [5]. The 5-tier 
pyramid, as shown on the left side of figure 1, describes the different types of public health 
interventions, with the potential impact being greater the closer the intervention type is to 
the base. While there is a place for public health efforts at all levels of the pyramid, 
challenges and available resources pragmatically dictate that effort should be placed as low 
on the pyramid as is feasible. In the case of tier 1 genomic applications, this means that, at 
present, much of the public health focus should be placed specifically on the level ‘changing 
the context to make default individual’s decisions healthy’; in other words: policy 
interventions.
Policy Interventions
Despite the inherent challenges of coordinating with multiple unconnected payer and 
provider networks within the US health care system, strategies to influence policy within 
states can be effective. Consider the highly successful work of the model genomics program 
started in Michigan, which worked closely with health care partners to extend health 
insurance coverage consistent with the USPSTF recommendation for BRCA genetic 
counseling and evaluation to over 6.6 million additional people within its borders by 2011 
[13]. Similar work aimed at state and national reimbursement guidelines is also critical. As 
shown in figure 1, other strategies could include leveraging such partnerships to add 
questions to standard payer/provider data collection instruments in an attempt to identify 
patients who, by virtue of being relatives of probands, might be at risk and in need of further 
testing. Health care networks could also institute protocols including prepared letters/forms 
and policies to encourage affected persons within their system to reach out to their relatives 
to seek screening, even those who might not be under the same coverage system. Inclusion 
of family health history and other genomic information in electronic medical records 
standards is also important. Furthermore, policy changes aimed at incorporating relevant 
Bowen et al. Page 4













data fields which identify tier 1 condition status within cancer registries might be effective 
for programmatic linkage efforts and for surveillance and epidemiologic purposes.
Education
While at the top of the pyramid in terms of overall effectiveness, standard education/
communication instruments are needed as part of the effort to provide timely information to 
policy makers, to inform the public, providers, and other stakeholders about the issues, and 
to motivate individual and collaborative action. The development of standard, vetted 
instruments and messages that can be adapted by states will prevent duplication of effort and 
lower the costs of action in this area. Further, genomic tier 1 core competencies for health 
care providers at various levels, including those for primary care providers and oncologists, 
need to be developed and facilitated.
Surveillance
Public health surveillance is needed to collect data within populations concerning the need 
for, appropriate usage of, and impact of tier 1 applications. In order to maximize the ability 
to compare data, assess disparities and progress, and limit the costs of these efforts, it is 
useful for states to measure the same data elements. For example, common modules 
developed via state partnership for use through the Behavioral Risk Factor Surveillance 
System (BRFSS) and other surveillance approaches would offer many advantages. The 
BRFSS is a state-based telephone health survey system that collects information on health 
risk behaviors, preventive health practices and health care access primarily related to chronic 
disease and injury. For many states, the BRFSS is the only available source of timely, 
accurate data on health-related behaviors [14].
In the context of cancer, all states have cancer registries that collect information on the 
occurrence of cancer. These registries can be used to integrate information on hereditary 
breast, ovarian and CRC to track progress in implementation of tier 1 genomic applications 
[10].
Active Clinical Intervention Programs
Cascade screening programs for family members of affected persons identified through 
health care networks or registries should be considered. Electronic medical records could be 
used to help standardize/automate systematic identification methods. Pilot approaches 
should be developed and tested which are designed for the US health care system, and 
accountable care or integrated health care organizations should be considered for these early 
efforts. Projects for LS and CRC conducted at Ohio State University already provide some 
lessons learned. Ohio State University was among the first centers to demonstrate the 
feasibility of screening all newly diagnosed CRC cases for LS [10]. Experience gained from 
such initial efforts can be exported through shared protocols. In the future, public health can 
take active roles in cascade screening including assistance with the identification of affected 
family members using skills developed from other areas. For instance, state and local health 
departments can use their extensive experience – previously gained from outbreak 
investigations and sexually transmitted diseases tracking to reach people at risk and in need 
of intervention. However, in this case, there would be a genetic link from the patient case to 
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others at risk and not simply a common exposure. Ethical, legal and social implications 
regarding the unique nature of tier 1 programs would have to be considered and addressed 
appropriately at all times.
Public Health-Health Care Collaboration through a National State/Federal/Stakeholder 
Partnership
To accomplish all of these goals, a national coalition of public health agencies and health 
care providers/payers and other stakeholders is needed. The mutual support and economies 
of scale provided by an active and cohesive partnership may be the best means of 
collectively navigating the unusual challenges of these applications for effectively reaching 
thousands of people with tier 1 conditions. Furthermore, strong collaborations are needed to 
coordinate the collective resources needed for successful implementation.
Next Steps for State Public Health Departments to Consider
Among, the strategies above, there are several action steps that state public health 
departments can take now for integrating tier 1 genomic applications beyond NBS into their 
programs, including: (1) review and build on the previous success of the model state public 
health genomics programs (the Michigan program mentioned earlier as just one example 
[13]); (2) participate in the development of, and then share standardized protocols for, 
engaging payer/provider partners in states; (3) participate in the development and 
distribution of standardized and vetted communication/education materials on tier 1 
applications for the public, payers, providers and policy makers; (4) participate in the 
development of a standard BRFSS module that can be used in every state, and through 
collaboration with partners, identify opportunities with provider and payer data systems to 
measure progress; (5) participate in the building of a federal or nationwide state action group 
for tier 1 genomic application implementation, with the ultimate goal of involving all states; 
(6) conduct pilot projects in a few states to examine the feasibility, scalability and cost-
effectiveness of implementing active cascade screening programs; (7) build successful 
relationships with payers, providers, advocacy groups, and other stakeholders within the 
state to implement policy interventions, set goals and monitor results; (8) explore 
opportunities for funding additional tier 1 application intervention programs/efforts through 
federal grants and nongovernmental organizations; (9) stay abreast of changes in the field as 
emerging genomic applications with sufficient evidence for implementation become 
available.
Concluding Remarks
Because of hype and disappointment regarding the availability of genomic applications with 
sufficient evidence to integrate into practice, many policy makers, providers, payers, and 
patients may have taken an understandable ‘wake me when we arrive’ approach to the field. 
However, both medicine and public health can act now to implement an increasing number 
of tier 1 genomic applications. Just as the first NBS efforts overcame substantial obstacles, 
reaching full impact with the 3 genomic testing applications requires that significant 
challenges be addressed. However, there are several, clear next steps that state public health 
departments can now take collectively to reap ‘low-hanging fruit’ for each of the 3 tier 1 
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applications discussed. Most of these immediate opportunities involve policy interventions 
and require partnerships with clinical health care providers and payers. These ‘trail blazing’ 
implementation efforts, including those already underway by model programs like 
Michigan, will provide valuable experience, as additional tier 1 applications will emerge in 
coming years. Next generation tools will likely be based on newer molecular technology but 
will also focus on common variants for common chronic diseases. Furthermore, it is likely 
that cascade screening methodology will remain an important strategy for implementing 
these future applications.
Today, public health operates in a world of rapidly changing technology, ambitious impact 
goals and limited resources. In this environment, past approaches may not be good enough, 
and the value of emerging tools, including genomic applications, should continually be 
assessed in an effort to improve the results of all traditional programs. Public health should 
continue to pursue new evidence based technologies and methods to improve the reach and 
quality of NBS. Meanwhile, tier 1 applications offer the potential to expand on the success 
of established state-based genetics and chronic disease programs to impact even more lives.
Appendix
BRCA1/2: Reducing the Burden of Breast and Ovarian Cancer among 
Women at Increased Hereditary Risk
About 2–7% of breast cancer and 10–15% of ovarian cancer are due to inherited genetic 
changes in the BRCA1 or BRCA2 genes [15]. These percentages translate to approximately 
10,000 cases of breast cancer and 2,700 cases of ovarian cancer that are associated with 
BRCA1/2 mutations each year in the US, based on 2012 estimates for new cases of breast 
and ovarian cancer [16, 17]. For women with a BRCA1/2 mutation that is clinically 
important, the probability of developing breast or ovarian cancer by the age of 70 is 
estimated to be between 35–84% (breast) and 10–50% (ovarian) [6].
The USPSTF recommends that women with certain high risk patterns of family health 
history of breast and ovarian cancer associated with BRCA1/2 mutations be referred for 
genetic counseling and evaluation by suitably trained health care providers to promote 
informed decision-making about genetic testing [6]. The USPSTF found fair evidence that 
for women with BRCA1/2 mutations, prophylactic bilateral mastectomy reduces breast 
cancer risk by 85% or more, and prophylactic oophorectomy reduces ovarian cancer risk by 
85% or more and breast cancer risk by 53% or more [6]. Other interventions might include 
intensive screening, chemoprevention, risk avoidance, or a combination of these; however, 
high-quality data on the effectiveness of these interventions may be limited [18]. There is 
evidence that there is both underutilization [9] and disparities in the availability and/or 
uptake [19] of BRCA genetic services.
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LS: Preventing CRC in Families at Increased Hereditary Risk Is Cost 
Effective
LS is the most common cause of inherited CRC, and about 3% of CRC cases are due to this 
condition. Mutations in mismatch repair (MMR) genes confer a lifetime CRC risk of 54–
74% in males and 30–52% in females, and screening colonoscopy at 1- to 3-year intervals 
among people with LS can reduce risk by about 60%. Based on the number of CRC cases 
diagnosed in the US in 2007 alone (143,000), an estimated 4,200 cases were due to LS [10]. 
LS may affect as many as 800,000 people in the US, and an estimated 98% of these people 
may be undiagnosed [20].
The Evaluation of Genomic Applications in Practice and Prevention recommends that 
genetic testing for LS be offered to all persons with newly diagnosed CRC and that cascade 
screening then be used to reach relatives, creating a unique opportunity to prevent CRC, 
through increased surveillance where indicated, in thousands of people using relatively 
inexpensive tests [8, 10]. Furthermore, an analysis conducted in 2009 found that this 
cascading approach is cost effective – being at least comparable with other preventive 
services [21].
FH: Preventing Cardiovascular Disease in Families at Increased Hereditary 
Risk
FH is a disorder characterized by high levels of low-density lipoprotein cholesterol in the 
blood, which results in increased risks of premature coronary heart disease (CHD) and 
death. In fact, there is a cumulative risk of CHD that is greater than 50% in men by the age 
of 50 and is at least 30% in women by the age of 60 for those with heterozygous FH (those 
who have inherited one disease-causing mutation) and includes a 100-fold increase in 
mortality from CHD for people under the age of 40 [22, 23]. FH is one of the most common 
inherited disorders, with a worldwide prevalence of 1 in 500 (which translates into 
approximately 13 million persons worldwide and 600,000 people in the US affected with 
FH) [22]. It is estimated that at least 75% of FH cases are not diagnosed, though many could 
be found efficiently since 50% of first degree relatives are also affected [22]. Statin 
treatment to lower serum low-density lipoprotein cholesterol levels is highly effective and 
has been shown to reduce morbidity and mortality, making it important to identify affected 
persons early [22]. Consistent drug compliance is important in cases of FH, since dietary 
and other behavioral interventions are not enough to treat the condition [22, 24]. If people in 
the US with undiagnosed FH could be identified and provided a cholesterol-reducing 
medication, thousands of heart attacks each year could be prevented (see table 1).
The 2008 National Institute for Health and Clinical Excellence guideline recommends that 
cascade screening be initiated from identified FH cases in the UK to include at least first- 
and second-degree relatives [7]. There is a need to assess the potential development of 
evidence-based FH recommendations designed specifically for the US health care system. 
Regardless, there are opportunities to apply what has been learned in the UK to the US 
environment now.
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Health impact pyramid applied to tier 1 genomics applications. Original pyramid by Frieden 
[12].
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